The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 14, 2015

Filed:

Sep. 30, 2005
Applicants:

Gottfried Himmler, Vienna, AT;

G. C. Mudde, Breitenfurt, AT;

Ralf Kircheis, Vienna, AT;

Thomas William Rademacher, Oxford, GB;

Soledad Penades Ullate, San Sebastian, ES;

Manuel Martin Lomas, San Sebastian, ES;

Jose Luis DE Paz Carrera, Seville, ES;

Rafael Ojeda Martinez DE Castilla, Seville, ES;

Africa Garcia Barrientes, Madrid, ES;

Inventors:

Gottfried Himmler, Vienna, AT;

G. C. Mudde, Breitenfurt, AT;

Ralf Kircheis, Vienna, AT;

Thomas William Rademacher, Oxford, GB;

Soledad Penades Ullate, San Sebastian, ES;

Manuel Martin Lomas, San Sebastian, ES;

Jose Luis De Paz Carrera, Seville, ES;

Rafael Ojeda Martinez De Castilla, Seville, ES;

Africa Garcia Barrientes, Madrid, ES;

Assignee:

Midatech Ltd., Abingdon, Oxford, Oxfordshire, GB;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/14 (2006.01); A61K 39/00 (2006.01); A61P 37/00 (2006.01); B82Y 5/00 (2011.01); A61K 39/39 (2006.01); A61K 47/48 (2006.01);
U.S. Cl.
CPC ...
B82Y 5/00 (2013.01); A61K 39/0011 (2013.01); A61K 39/39 (2013.01); A61K 47/4833 (2013.01); A61K 47/48861 (2013.01); A61K 47/48884 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/6037 (2013.01); A61K 2039/625 (2013.01); A61K 2039/645 (2013.01);
Abstract

Nanoparticles comprising adjuvants and antigens, such as tumor and pathogen antigens, are disclosed and their use in a range of applications such as for the treatment of cancer and infectious diseases. Immunogenic structures based on nanoparticles or antibodies with carbohydrate ligands, and their use for therapeutic and prophylactic purposes, and for the isolation and detection of antibodies directed against the carbohydrate structures.


Find Patent Forward Citations

Loading…